[go: up one dir, main page]

RU2018145948A3 - - Google Patents

Download PDF

Info

Publication number
RU2018145948A3
RU2018145948A3 RU2018145948A RU2018145948A RU2018145948A3 RU 2018145948 A3 RU2018145948 A3 RU 2018145948A3 RU 2018145948 A RU2018145948 A RU 2018145948A RU 2018145948 A RU2018145948 A RU 2018145948A RU 2018145948 A3 RU2018145948 A3 RU 2018145948A3
Authority
RU
Russia
Application number
RU2018145948A
Other versions
RU2746045C2 (ru
RU2018145948A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018145948A publication Critical patent/RU2018145948A/ru
Publication of RU2018145948A3 publication Critical patent/RU2018145948A3/ru
Application granted granted Critical
Publication of RU2746045C2 publication Critical patent/RU2746045C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/005Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2018145948A 2016-06-16 2017-06-15 Кристалл пирролопиримидина для получения jak-ингибитора RU2746045C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610435947.4 2016-06-16
CN201610435947.4A CN107759600A (zh) 2016-06-16 2016-06-16 作为jak抑制剂的吡咯并嘧啶化合物的结晶
PCT/CN2017/088429 WO2017215630A1 (zh) 2016-06-16 2017-06-15 作为jak抑制剂的吡咯并嘧啶化合物的结晶

Publications (3)

Publication Number Publication Date
RU2018145948A RU2018145948A (ru) 2020-07-16
RU2018145948A3 true RU2018145948A3 (ru) 2020-10-16
RU2746045C2 RU2746045C2 (ru) 2021-04-06

Family

ID=60664302

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018145948A RU2746045C2 (ru) 2016-06-16 2017-06-15 Кристалл пирролопиримидина для получения jak-ингибитора

Country Status (11)

Country Link
US (1) US10626118B2 (ru)
EP (1) EP3473626B1 (ru)
JP (1) JP6986032B2 (ru)
KR (1) KR102523564B1 (ru)
CN (2) CN107759600A (ru)
AU (1) AU2017284702B2 (ru)
CA (1) CA3026602A1 (ru)
ES (1) ES2886910T3 (ru)
RU (1) RU2746045C2 (ru)
TW (1) TWI753918B (ru)
WO (1) WO2017215630A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107513069A (zh) * 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
CN107759600A (zh) 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
US20220072002A1 (en) 2018-12-24 2022-03-10 Chia Tai Tianqing Pharmaceuticalgroup Co., Ltd. Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12447154B2 (en) 2020-03-09 2025-10-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome
US20240285635A1 (en) * 2021-06-21 2024-08-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease
CN120459106A (zh) 2022-03-21 2025-08-12 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途
CN120882718A (zh) * 2023-03-17 2025-10-31 北京普祺医药科技股份有限公司 吡咯并嘧啶化合物或其可药用盐的制备方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
CN119528911B (zh) * 2024-10-21 2025-11-28 南通常佑药业科技有限公司 一种芦可替尼的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2426129T1 (sl) * 2005-12-13 2017-02-28 Incyte Holdings Corporation Heteroarilno substituirani pirolo(2,3-b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janusove kinaze
RU2496780C2 (ru) * 2006-10-27 2013-10-27 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Твердые формы
MX342814B (es) * 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2013173506A2 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
CN105218548A (zh) * 2014-06-09 2016-01-06 上海海和药物研究开发有限公司 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
EP3183253B1 (en) * 2014-08-21 2018-06-27 ratiopharm GmbH Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
CN107759600A (zh) 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶

Also Published As

Publication number Publication date
TW201800413A (zh) 2018-01-01
EP3473626B1 (en) 2021-08-04
CA3026602A1 (en) 2017-12-21
US20190330215A1 (en) 2019-10-31
AU2017284702B2 (en) 2021-05-06
CN109311891B (zh) 2020-09-04
ES2886910T3 (es) 2021-12-21
RU2746045C2 (ru) 2021-04-06
KR20190017977A (ko) 2019-02-20
JP6986032B2 (ja) 2021-12-22
RU2018145948A (ru) 2020-07-16
CN107759600A (zh) 2018-03-06
TWI753918B (zh) 2022-02-01
US10626118B2 (en) 2020-04-21
WO2017215630A1 (zh) 2017-12-21
CN109311891A (zh) 2019-02-05
KR102523564B1 (ko) 2023-04-19
EP3473626A4 (en) 2020-02-19
JP2019521980A (ja) 2019-08-08
AU2017284702A1 (en) 2019-01-24
EP3473626A1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
BR112019009389A2 (ru)
BR122021013712A2 (ru)
BR122020022459A2 (ru)
BR112019009192A2 (ru)
BR112019006736A2 (ru)
BR202016025584U2 (ru)
BR202016021516U2 (ru)
CN303537689S (ru)
CN303538000S (ru)
CN303536129S (ru)
CN303536208S (ru)
CN303536232S (ru)
CN303536246S (ru)
CN303536269S (ru)
CN303536362S (ru)
CN303536516S (ru)
CN303536549S (ru)
CN303536736S (ru)
CN303537271S (ru)
CN303537358S (ru)
CN303537427S (ru)
CN303537519S (ru)
CN303537566S (ru)
CN303537608S (ru)
CN303641596S (ru)